Global Biosimilars Market 2014-2018

Reportstack Announces the Publication of its Research Report - Global Biosimilars Market 2014-2018. The following companies are the key players in Global Biosimilars Market: Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., and 3SBio Inc.

“The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. ”

According to the report, one of the main drivers in this market is the increasing number of patent expirations. A number of biopharmaceutical patents are due to expire in the near future or have already expired. This has helped propel the growth of vendors in the Global Biosimilars market. Some of the blockbuster drugs that are expected to lose patent expiry are Remicade, Humira, and Rituxan.

Further, the report states that one of the key challenges in the market is the risks related to drug failure. Vendors face a high level of risk due to the huge investments involved in the development stage and the possible failure of drugs when launched.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit http://www.reportstack.com/product/150774/global-biosimilars-market-2014-2018.html